Monolaurin

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: immunity inflammation digestion

Research Overview

Across the studies reviewed here, monolaurin (glycerol monolaurate) is most frequently studied for antimicrobial applications, particularly against Staphylococcus aureus (including MRSA) and, to a lesser extent, fungal biofilms such as Candida albicans. A second, more formulation-focused area concerns its behavior as a nonionic surfactant in topical contexts (e.g., vaginal prophylaxis concepts), where cytotoxicity to relevant mammalian cell types is evaluated in vitro. Outside of direct antimicrobial activity, monolaurin also appears in materials/food-structure research as a monoacylglyceride component affecting crystallization and stability in oil-based foams, indicating interest in its physicochemical functionality beyond biomedicine.

The strongest evidence in these studies supports in vitro antimicrobial activity and potential synergy with conventional antibiotics against S. aureus. Reported MICs against clinical S. aureus isolates are in the hundreds to low thousands of µg/mL, with microscopy suggesting membrane-associated morphological disruption, and gene-expression data indicating reduced blaZ (β-lactamase) expression under monolaurin exposure in some settings. Multiple in vitro combination studies report high rates of synergism between monolaurin and β-lactam antibiotics (by FIC and time-kill approaches), consistent with a role as an antibiotic activity modulator. For fungi, the evidence supports antifungal effects against C. albicans in vitro, including reductions in biofilm viability at higher concentrations and associated down-regulation of host inflammatory cytokine transcripts (IL-1α/IL-1β) in a co-culture model, suggesting both antimicrobial and host-response modulation under experimental conditions.

Key gaps are translational: most findings are in vitro, with limited information here on in vivo efficacy, pharmacokinetics, optimal delivery systems, and clinically relevant dosing. Safety and tolerability also require more systematic study in intended-use contexts: the surfactant toxicology work indicates monolaurin can be cytotoxic to multiple mammalian cell types at concentrations near its critical micelle concentration, implying a potentially narrow margin between antimicrobial activity and host-cell effects depending on formulation and exposure. Additional research is needed to define mechanisms of synergy with antibiotics (including whether effects on resistance determinants generalize beyond blaZ and beyond S. aureus), to standardize susceptibility testing conditions (which can strongly influence MICs), and to evaluate biofilm activity in clinically realistic models (e.g., device-associated biofilms in vivo). Finally, while monolaurin is discussed in contexts ranging from topical prophylaxis to food/material applications, the evidence base would benefit from comparative studies versus other monoglycerides and from controlled clinical studies to establish real-world effectiveness and safety.

1. What conditions has Monolaurin been studied for?

  • Bacterial infections (primarily Staphylococcus aureus): including general S. aureus isolates and methicillin-resistant S. aureus (MRSA), with attention to antibiotic resistance mechanisms (e.g., beta-lactamase) and combination therapy with β-lactam antibiotics.

  • Biofilm-associated infections: MRSA biofilm development and pre-existing biofilms; also explored in a wound-healing infection model using monolaurin lipid nanocapsules (ML-LNCs) against S. aureus biofilms.

  • Fungal infection: Candida albicans biofilms relevant to oral candidiasis, including effects on host inflammatory cytokine expression (IL-1α, IL-1β) in an oral fibroblast co-culture model.

  • Topical/vaginal prophylaxis context: studied as a surfactant in vitro for toxicity toward vaginally relevant mammalian cell types (polarized and non-polarized epithelial cells, dendritic cells) and human sperm, in the context of designing topical formulations for STI prophylaxis.

  • COVID-19 risk association (observational): circulating monolaurin levels were associated with “protection” from SARS-CoV-2 infection in a small healthcare-worker metabolomics study (association, not supplementation trial).

  • Drug/nutrient delivery research: used as a lipid component in solid lipid nanoparticles (e.g., for ferrous sulfate encapsulation) and in lipid nanocapsules for antimicrobial delivery (formulation research rather than a clinical condition per se).

2. Does it work in treating those conditions? Summarize the evidence.

  • S. aureus (in vitro antibacterial activity): In 115 S. aureus isolates, monolaurin showed MICs of 250–2000 µg/mL. Electron microscopy showed morphological changes (cell elongation and outer membrane swelling) at 1×MIC, supporting a direct antibacterial effect in vitro.

  • Synergy with β-lactam antibiotics (in vitro): The same S. aureus study reported that monolaurin reduced blaZ (beta-lactamase) gene expression at 250 and 500 µg/mL and found synergistic interactions with β-lactams, with reported synergism rates of 83.3% to 100% by FIC and time-kill methods. This supports a potential “antibiotic-modulating” effect in vitro.

  • MRSA and biofilms (in vitro): An MRSA-focused abstract reports monolaurin MICs of approximately 500–2000 (units truncated in the provided text, but consistent with µg/mL in related work) and concludes monolaurin significantly inhibited biofilm development and impacted pre-existing biofilms. This supports antibiofilm activity in vitro, but details (e.g., IC values, magnitude) are not fully available in the excerpt.

  • Infected wound model (in vivo translation): In a murine infected wound-healing model, monolaurin lipid nanocapsules (ML-LNCs) showed in-vitro synergy with an antimicrobial peptide (DPK-060) against S. aureus biofilms, but the faster, synergistic wound-healing seen in vitro was absent in vivo. This suggests that promising in-vitro synergy may not reliably translate to clinical benefit.

  • Oral candidiasis / Candida albicans biofilms (in vitro): Monolaurin had MIC/MFC ranges of 62.5–125 µM and 125–250 µM, respectively, against C. albicans. Biofilm assays showed significant CFU reductions at 1250 and 2500 µM. In a co-culture model, monolaurin also down-regulated host IL-1α and IL-1β expression. This supports antifungal and anti-inflammatory signaling effects in vitro, but not clinical efficacy.

  • COVID-19 (association only): A small metabolomics study (51 healthcare workers) found higher circulating monolaurin in those who did not develop COVID-19 after exposure, suggesting a potential defensive role. However, this is observational and does not show that taking monolaurin prevents infection.

  • STI prophylaxis context (safety/toxicity, not efficacy): In vitro, monolaurin was toxic to multiple mammalian cell types at concentrations around its critical micelle concentration (CMC), consistent with non-selective membrane-disrupting surfactant effects. This does not demonstrate STI prevention; it primarily informs safety constraints for topical use.

3. What health benefits does it have?

  • Antibacterial activity (in vitro): Demonstrated inhibition of S. aureus growth with MICs in the 250–2000 µg/mL range, with microscopy evidence of bacterial structural damage.

  • Potential antibiotic “adjuvant” effect (in vitro): Reduced blaZ expression (beta-lactamase) and showed strong in-vitro synergy with β-lactam antibiotics (FIC and time-kill), suggesting it might help restore or enhance β-lactam activity against some S. aureus isolates.

  • Antibiofilm activity (in vitro): Reported inhibition of MRSA biofilm formation and effects on established biofilms, which is relevant because biofilms contribute to chronic and device-associated infections.

  • Antifungal activity against Candida (in vitro): Inhibited C. albicans and reduced biofilm burden at higher concentrations; also associated with reduced host pro-inflammatory cytokine gene expression (IL-1α/IL-1β) in a co-culture model.

  • Possible association with lower COVID-19 risk (hypothesis-generating): Higher endogenous monolaurin levels correlated with not developing COVID-19 in a small cohort, but this does not establish supplementation benefit.

Overall, the benefits supported by these studies are primarily preclinical (in vitro), with limited and mixed in vivo translation in the wound model and no direct clinical trials described in the provided text.

4. Does it have any downsides or side effects?

  • Cell toxicity as a surfactant (in vitro): In a study comparing surfactants relevant to vaginal exposure, monolaurin was toxic to multiple mammalian cell types (polarized and non-polarized epithelial cells, dendritic cells) and also affected human sperm at concentrations around its CMC, consistent with non-selective membrane disruption. This raises caution for topical mucosal use at sufficiently high concentrations.

  • Narrow safety window may be formulation-dependent: The surfactant toxicology findings imply that dose/concentration and exposure time matter, and that safety may depend heavily on how monolaurin is formulated (e.g., gels, nanoparticles) and what concentrations are achieved at tissues.

  • In vivo efficacy limitations: In the infected wound model, in-vitro synergy did not translate into synergistic in-vivo healing, highlighting a “downside” from a practical standpoint: promising lab effects may not yield real-world benefit.

The studies reviewed here do not report typical supplement side effects (e.g., gastrointestinal symptoms) or human adverse-event rates; the clearest safety signal here is in-vitro cytotoxicity at surfactant-like concentrations relevant to topical exposure.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not identify human genetic variants that predict response or risk from monolaurin supplementation (i.e., no pharmacogenomic findings).

  • Bacterial gene context (not human pharmacogenomics): One study measured the bacterial blaZ gene (beta-lactamase) and found monolaurin reduced its expression at certain concentrations, which may help explain synergy with β-lactams in vitro. This is a microbial resistance mechanism, not a human genetic variation.

Conclusion: based on these studies, there is insufficient evidence to claim monolaurin is beneficial or harmful for specific human genetic variants; the only gene-related data concern bacterial resistance gene expression.

References

  1. In vitro surfactant structure-toxicity relationships: implications for surfactant use in sexually transmitted infection prophylaxis and contraception.
    Ângela S Inácio, Katia A Mesquita, Marta Baptista, João Ramalho-Santos, Winchil L C Vaz, Otília V Vieira (2011) - PloS one
  2. Novel synergistic interactions between monolaurin, a mono-acyl glycerol and β lactam antibiotics against Staphylococcus aureus: an in vitro study.
    Shimaa Salah Hassan Abd El Ghany, Reham A Ibrahem, Ahmed Osama El-Gendy, Rehab Mahmoud Abd El-Baky, Ahmad Mustafa, Ahmed Farag Azmy (2024) - BMC infectious diseases
  3. Oleofoams stabilized by monoacylglycerides: Impact of chain length and concentration.
    Matteo Grossi, Baochen Fang, Jiajia Rao, Bingcan Chen (2023) - Food research international (Ottawa, Ont.)
  4. Antimicrobial and Antibiofilm Activity of Monolaurin against Methicillin-Resistant
    Shimaa Salah Hassan Abd El-Ghany, Ahmed Farag Azmy, Ahmed Osama El-Gendy, Rehab Mahmoud Abd El-Baky, Ahmad Mustafa, Mohammed A S Abourehab, Mohamed E El-Beeh, Reham Ali Ibrahem (2024) - International journal of microbiology
  5. In Vitro Antibacterial Activities and Mechanisms of Action of Fatty Acid Monoglycerides Against Four Foodborne Bacteria.
    Wenyue Wang, Rui Wang, Guiju Zhang, Fangli Chen, Baocai Xu (2020) - Journal of food protection
  6. Antimicrobial treatments to control Listeria monocytogenes in queso fresco.
    António Lourenço, Mary B Kamnetz, Camila Gadotti, Francisco Diez-Gonzalez (2017) - Food microbiology
  7. In vitro evaluation of antifungal activity of monolaurin against Candida albicans biofilms.
    Dalia Seleem, Emily Chen, Bruna Benso, Vanessa Pardi, Ramiro M Murata (2016) - PeerJ
  8. Understanding protection from SARS-CoV-2 using metabolomics.
    Elettra Barberis, Elia Amede, Matteo Tavecchia, Emilio Marengo, Micol G Cittone, Eleonora Rizzi, Anita R Pedrinelli, Stelvio Tonello, Rosalba Minisini, Mario Pirisi, Marcello Manfredi, Pier Paolo Sainaghi (2021) - Scientific reports
  9. Preparation of Solid Lipid Nanoparticle-Ferrous Sulfate by Double Emulsion Method Based on Fat Rich in Monolaurin and Stearic Acid.
    Edy Subroto, Robi Andoyo, Rossi Indiarto, Endah Wulandari, Elgi Fadhilah Nadhirah Wadhiah (2022) - Nanomaterials (Basel, Switzerland)
  10. Antimicrobial synergy of monolaurin lipid nanocapsules with adsorbed antimicrobial peptides against Staphylococcus aureus biofilms in vitro is absent in vivo.
    René T Rozenbaum, Linzhu Su, Anita Umerska, Matthieu Eveillard, Joakim Håkansson, Margit Mahlapuu, Fan Huang, Jianfeng Liu, Zhenkun Zhang, Linqi Shi, Henny C van der Mei, Henk J Busscher, Prashant K Sharma (2019) - Journal of controlled release : official journal of the Controlled Release Society
  11. Evaluation of Natural and Botanical Medicines for Activity Against Growing and Non-growing Forms of
    Jie Feng, Jacob Leone, Sunjya Schweig, Ying Zhang (2020) - Frontiers in medicine
  12. Synergistic interactions between antimicrobial peptides derived from plectasin and lipid nanocapsules containing monolaurin as a cosurfactant against
    Anita Umerska, Viviane Cassisa, Guillaume Bastiat, Nada Matougui, Hassan Nehme, Florence Manero, Matthieu Eveillard, Patrick Saulnier (2017) - International journal of nanomedicine
  13. Effects of monolaurin on intestinal barrier, blood biochemical profile, immunity and antioxidant function in porcine epidemic diarrhoea virus-infected piglets.
    Chao Wang, Qian Zhang, Changzheng Ji, Yuyan Hu, Dan Yi, Tao Wu, Lei Wang, Di Zhao, Yongqing Hou (2024) - The British journal of nutrition
  14. Evaluation of different blends of medium-chain fatty acids, lactic acid, and monolaurin on nursery pig growth performance
    Lori L Thomas, Jason C Woodworth, Mike D Tokach, Steve S Dritz, Joel M DeRouchey, Robert D Goodband, Hayden E Williams, Ashley R Hartman, Dillon J Mellick, Denny M McKilligan, Aaron M Jones (2020) - Translational animal science
  15. The Antiviral Activity of Caprylic Monoglyceride against Porcine Reproductive and Respiratory Syndrome Virus In Vitro and In Vivo.
    Luyu Yang, Jianhua Wen, Yang Zhang, Zheyan Liu, Zhipeng Luo, Lei Xu, Siyuan Lai, Huaqiao Tang, Xiangang Sun, Youjun Hu, Ling Zhu, Zhiwen Xu (2022) - Molecules (Basel, Switzerland)
  16. Monolaurin Confers a Protective Effect Against Porcine Epidemic Diarrhea Virus Infection in Piglets by Regulating the Interferon Pathway.
    Qian Zhang, Dan Yi, Changzheng Ji, Tao Wu, Manli Wang, Shuangshuang Guo, Lei Wang, Di Zhao, Yongqing Hou (2021) - Frontiers in immunology
  17. Decylglucoside-based microemulsions for cutaneous localization of lycopene and ascorbic acid.
    Dominique Pepe, Jessica Phelps, Kevin Lewis, Jared Dujack, Katrina Scarlett, Sumaya Jahan, Emilee Bonnier, Tatjana Milic-Pasetto, Martha A Hass, Luciana B Lopes (2012) - International journal of pharmaceutics
  18. Comprehensive investigation on the synergistic antibacterial activities of Jatropha curcas pressed cake and seed oil in combination with antibiotics.
    Abdul Haq, Maleeha Siddiqi, Syeda Zakia Batool, Arshad Islam, Alam Khan, Dildar Khan, Samiullah Khan, Haji Khan, Aamer Ali Shah, Fariha Hasan, Safia Ahmed, Malik Badshah (2019) - AMB Express
  19. Activity of virgin coconut oil, lauric acid or monolaurin in combination with lactic acid against Staphylococcus aureus.
    Pussadee Tangwatcharin, Prapaporn Khopaibool (2012) - The Southeast Asian journal of tropical medicine and public health


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!